SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the community debates the impact of a recent purchase of TSLA stock by Elon Musk, with some seeing it as a positive signal and others suspecting market manipulation. Concerns about global sales figures and increasing competition in the EV sector are also being discussed alongside speculation about future ventures like AI and robotics. The stock's volatile price action is fueling both bullish and bearish sentiment, with traders closely watching key technical levels.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending as community members discuss its potential role in powering AI data centers and strategic uranium reserves. Bullish sentiment is fueled by the company's innovative approach to nuclear energy, while others express concerns about its current valuation and lack of revenue. Traders are actively debating entry and exit points as the stock experiences volatility.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as the community rallies around its decentralized nature and Bitcoin foundation, touting it as more than just a memecoin but a movement. Conversations highlight its fair distribution and organic community, with some mentioning a Coinbase listing review. The broader discussion centers on $DOG.X being the premier memecoin on the Bitcoin network.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Asset Entities Inc.

Asset Entities Inc. ($ASST) is trending due to volatility following its merger, with community members debating the impact of a recently announced offering and buyback program. Discussions also revolve around high short interest, margin requirements, and borrow fees, with some traders hoping for a potential short squeeze, while others express concern about dilution and trading restrictions on some platforms.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as the community discusses its potential as a major cloud provider following the Northern Data acquisition, with some highlighting Tether's increased ownership and the upcoming Rumble wallet. Community members are also focused on the platform's ties to figures in the Trump administration, anticipating a shift in media spending and spotlighting the all-time high short interest as a possible squeeze opportunity.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending amid community discussions around a potential short squeeze, driven by high short interest and option activity. Some traders are pointing to recent partnerships and technical indicators as bullish signals, while others caution about potential dilution and overvaluation, contributing to the stock's volatility. Broader interest in the quantum computing sector and upcoming catalysts, such as DARPA funding, may also be influencing the conversation.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels Inc. is trending as conversations revolve around the potential for government contracts and its strategic positioning in uranium and rare earth elements. Community members are actively discussing the company's dual narrative and debating whether it is currently undervalued. The stock's movement is also influenced by broader trends in the uranium sector and discussions around energy independence.

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Helius Medical Technologies Inc - Ordinary Shares - Class A

Helius Medical Technologies Inc

HSDT is experiencing significant volatility as traders discuss a recent partnership announcement focused on Solana cryptocurrency. Community members are pointing to unusual volume and potential short squeezes, while also debating the merits of the company's new crypto strategy and upcoming catalysts. The stock is garnering attention as a low float runner and potential pump and dump, with some traders citing technical indicators and prior price action.

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics ($GLUE) is trending due to a licensing agreement with Novartis potentially worth up to $5.7 billion, sparking excitement about the company's future and potential for significant growth. The community is discussing potential short squeezes and target prices, with some speculating about a possible acquisition. Some traders are noting the high short interest and unusual volume, while others discuss possible resistance levels and near-term price movements.

$VINU - The OG meme of BNB Smart Chain since 2021.   VINU isn't just another memecoin—it's a dynamic cultural phenomenon that transcends traditional cryptocurrency.   More than digital currency, VINU represents a vibrant community where meme enthusiasts, crypto pioneers, and free thinkers unite. VINU champions humor, creativity, and the revolutionary spirit of blockchain innovation.  Enter the Vinuverse.

Vita Inu 

Vita Inu (VINU.X) is trending as community members highlight its low price point and potential for significant gains, drawing comparisons to other meme coins like DOGE and SHIB. Some users are speculating about potential exchange listings and a possible bridge to Solana. Community members are also discussing the coin's utility, staking rewards, metaverse, and multi-chain support.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail chatter around Moleculin Biotech surged on Monday after the company said the European Medicines Agency had approved its Clinical Trial Application for a pivotal Phase 2B/3 study of Annamycin in combination with cytarabine for patients with relapsed or refractory acute myeloid leukemia.The European Medicines Agency approved the randomized, placebo-controlled trial in all nine European Union countries where Moleculin Biotech filed it.&nbsp;It will include research locations in the U.S. and the Middle East.&nbsp;Moleculin Biotech shares closed 2.86% higher at $1.08 on Monday, before slipping 3.7% to $1.04 in after-hours trading.Researchers will combine the Phase 2B study with Phase 3 testing to measure primary efficacy according to international regulatory requirements.Part A of the trial will recruit between 75 and 90 patients randomly assigned to receive HiDAC with a placebo or one of two FDA-approved Annamycin doses of 190 mg/m² or 230 mg/m².&nbsp;The initial patient data set from 45 participants will become available during the second semester of 2025, and researchers anticipate the second unblinding to occur at the beginning of 2026.&nbsp;The trial will expand to include approximately 220 patients during Phase 3 enrollment (Part B).EMA approval depends on Moleculin providing nonclinical GLP data before starting Part B, necessitating protocol modifications afterward.&nbsp;The trial uses an adaptive design that supports the FDA’s Project Optimus goal of improved oncology dose selection.The company remains on course to deliver its expected interim readout this year, as patient dosing has already started.On Stocktwits, retail sentiment was ‘bullish’ amid a 3,700% surge in 24-hour message volume.Some traders expressed appreciation for the stock’s steady performance, with one noting that market makers were doing a good job “keeping it tight” for those accumulating shares of Moleculin.<stembedurl>https://stocktwits.com/CrisMars/message/614378232</stembedurl>Another described the 2.86% rise of the stock as “decent” and said “low and slow will win the race.”<stembedurl>https://stocktwits.com/BiggPapa/message/614389064</stembedurl>The stock has declined nearly 39% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Moleculin Biotech Gets EMA Nod For Leukemia Trial: Retail Feels Bullish On ‘Low And Slow’ Setup 

The trial, which will involve sites in the U.S., Europe, and the Middle East, aims to combine Phase 2B and Phase 3 data for efficacy evaluation of the Miracle trial of Annamycin for relapsed or refractory acute myeloid leukemia.

Equity

AIM ImmunoTech, Inc. (1100% jump in message volume)AIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 trial for Ampligen and AstraZeneca’s (AZN) Imfinzi in late-stage pancreatic cancer treatment. Several Phase 1 patients who received the highest dose will also be included in Phase 2. The trial, known as DURIPANC, is taking place in the Netherlands and will enroll up to 25 patients in this phase.PepGen, Inc. (700% jump in message volume)PepGen shares and retail chatter <a href="https://stocktwits.com/news-articles/markets/equity/pepgen-stock-heads-for-best-week-since-sept-2022/chdghv2RyH">soared</a> after the company released early clinical data from its FREEDOM-DM1 Phase 1 trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1), a genetic disorder causing progressive muscle weakness. The company reported dose-dependent splicing correction of 12.3% at 5 mg/kg and 29.1% at 10 mg/kg at 28 days post-dosing.While single-dose studies haven’t shown functional improvements, PepGen sees early signs of benefits with repeat dosing. H.C. Wainwright called the data “very encouraging.”Aeon Biopharma, Inc. (700% jump in message volume)Aeon gained attention after announcing a 1-for-72 reverse stock split to meet NYSE American’s minimum share price requirement. The move took effect on Wednesday, with fractional shares rounded up.Last month, Aeon received a non-compliance notice from NYSE American for failing to meet the $2 million stockholders’ equity requirement. The company reported a $32.1 million stockholders’ deficit as of Sept. 30 and has suffered losses in its last two fiscal years. Aeon has until March 5 to submit a plan to regain compliance.Tiziana Life Sciences Ltd. (600% jump in message volume)Tiziana’s stock buzz jumped after a Nature Neuroscience study showed its nasal anti-CD3 monoclonal antibody significantly reduced neuroinflammation and improved recovery in a preclinical model of traumatic brain injury (TBI). The treatment correlated with less anxiety, reduced cognitive decline, and improved motor skills.Additionally, Tiziana revealed on Tuesday that its nasal anti-CD3 preclinical study is nearing completion and that foralumab could be a novel treatment for long COVID.Moleculin Biotech, Inc.&nbsp;(600% jump in message volume)Moleculin saw heightened retail discussion after announcing a $1.07 per share direct offering of about 3.3 million shares and warrants to an institutional investor, with 6.5 million warrants exercisable at $1.07 per share for five years.The company&nbsp;expected to close the offering on Feb. 26, with Roth Capital Partners as the placement agent. The company said proceeds would be used for working capital and general corporate purposes.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week

New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules Moleculin Announces Pricing of $3.5 Million Registered...

These five biotech stocks, all belonging to nano-, small- or mid-cap categories, notched the highest jump in Stocktwits message volume in the week ended Feb. 14, 2025:GlycoMimetics Inc. (+550% jump in chatter)GlycoMimetics, a late-stage biotech firm developing glycobiology-based cancer therapies, saw a surge in retail interest after a minor amendment to its merger agreement with Crescent Biopharma. The update refined the financing structure but kept intact the exchange ratio and ownership split. Once the deal closes, Crescent security holders, including new investors, will own about 96.9% of the combined company. Shares are up roughly 16% year-to-date (YTD).GRAIL Inc. (+500% jump in chatter)Cancer detection firm GRAIL made waves after announcing a partnership with Quest Diagnostics (DGX) to distribute its Galleri multi-cancer early detection test. Analysts at Guggenheim viewed the move as a major step toward broader accessibility. The stock has soared over 208% YTD.ADMA Biologics Inc. (+400% jump in chatter)ADMA Biologics, a biopharma company focused on plasma-derived therapies, saw rising buzz ahead of its upcoming fourth-quarter (Q4) earnings. Last month, it issued a preliminary report projecting full-year 2024 revenue between $417 million and $425 million, with total cash holdings exceeding $100 million. Despite the strong forecast, shares remain down more than 8% YTD.Moleculin Biotech Inc. (+295% jump in chatter)Moleculin Biotech gained traction after the FDA provided guidance on its Phase 3 trial for Annamycin, a next-generation anthracycline designed to treat relapsed/refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases. With an adjusted trial size, the company expects its first unblinding in late 2025 and another in early 2026. Shares have climbed over 25% YTD.Exelixis Inc. (+200% jump in chatter)Exelixis, an oncology-focused biotech, saw a surge in discussions after reporting Q4 earnings that topped estimates, prompting analysts to raise their price targets. Citi highlighted continued strength in its Cabometyx franchise and pointed to Zanza as a potential blockbuster drug. Shares are up 4.35% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Top 5 Biotech Stocks That Got Most Retail Buzz Last Week

From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds PR Newswire HOUSTON, Feb. 13, 2025 HOUSTON, Feb. 13...

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML) Moleculin Receives Positive FDA Guidance for Acceleration of...

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial Moleculin Receives First Country Approval in Europe to...

Moleculin Participates in Virtual Investor "What This Means" Segment

Moleculin Participates in Virtual Investor 'What This Means' Segment Moleculin Participates in Virtual Investor 'What This Means' Segment PR Newswire HOUSTON, Jan. 27, 2025 Walter Klemp, CEO of...

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 and 2026

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026 Moleculin Highlights Development Progress of...

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model Moleculin Announces Online Publication of Preclinical Data...

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe in July 2015 and is headquartered in Houston, TX.

Moleculin Biotech Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

MBRX
Moleculin Biotech Inc

Feed

News

Sentiment

Fundamentals

Info

Latest MBRX News

MBRX Moleculin Biotech Inc